[
  {
    "ts": null,
    "headline": "Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics",
    "summary": "Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://finnhub.io/api/news?id=73a960707eb2441c9cdb31f8e33470313bccf268207a94558551ef47447d14eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769782510,
      "headline": "Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics",
      "id": 138307309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
      "url": "https://finnhub.io/api/news?id=73a960707eb2441c9cdb31f8e33470313bccf268207a94558551ef47447d14eb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock: Analyst Estimates & Ratings",
    "summary": "After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?",
    "url": "https://finnhub.io/api/news?id=e98d018219436d7dd5e47c6769ddad37c463cb0434308d3d09b7ff853ac2d77a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769781206,
      "headline": "AbbVie Stock: Analyst Estimates & Ratings",
      "id": 138307310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?",
      "url": "https://finnhub.io/api/news?id=e98d018219436d7dd5e47c6769ddad37c463cb0434308d3d09b7ff853ac2d77a"
    }
  },
  {
    "ts": null,
    "headline": "EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)",
    "summary": "Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found […]",
    "url": "https://finnhub.io/api/news?id=4429b7547556878acf97e4f60872798a6bdb6c20151af299eced0149685d29a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769756837,
      "headline": "EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)",
      "id": 138303544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found […]",
      "url": "https://finnhub.io/api/news?id=4429b7547556878acf97e4f60872798a6bdb6c20151af299eced0149685d29a0"
    }
  }
]